Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
20 Mar 24
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Nov 23
8-K
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
8 Nov 23
8-K
Other Events
1 Sep 23
8-K
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Departure of Directors or Certain Officers
8 Jun 23
8-K
Other Events
7 Jun 23
8-K
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
3 May 23
Registration and prospectus
S-3
Shelf registration
18 Apr 24
424B5
Prospectus supplement for primary offering
20 Mar 24
S-3
Shelf registration
8 Nov 23
S-8
Registration of securities for employees
9 Jun 22
S-8
Registration of securities for employees
28 Feb 22
S-3ASR
Automatic shelf registration
4 Nov 21
S-8
Registration of securities for employees
24 Feb 21
424B5
Prospectus supplement for primary offering
7 Jan 21
FWP
Free writing prospectus
5 Jan 21
424B5
Prospectus supplement for primary offering
4 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
PRE 14A
Preliminary proxy
7 Apr 21
Other
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
CT ORDER
Confidential treatment order
27 Feb 19
CT ORDER
Confidential treatment order
12 Sep 18
CT ORDER
Confidential treatment order
19 Jul 18
EFFECT
Notice of effectiveness
14 May 18
CORRESP
Correspondence with SEC
11 May 18
UPLOAD
Letter from SEC
11 May 18
CT ORDER
Confidential treatment order
19 Mar 18
Ownership
4
Jeremy Green
25 Mar 24
SC 13D/A
Redmile Group, LLC
25 Mar 24
4
Edward J Dulac III
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Boxer Capital, LLC
12 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
4
J Scott Wolchko
2 Feb 24
4
CINDY TAHL
2 Feb 24
4
Edward J Dulac III
2 Feb 24